Buprenorphine
15
2
4
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.7%
1 terminated out of 15 trials
90.0%
+3.5% vs benchmark
33%
5 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Peer Recovery Support for Opioid Use Disorder Treatment Retention
Injectable Buprenorphine in Prison: A Preference Trial
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD
Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis
The Effects of Opioid Taper on Opioid-Induced Hyperalgesia
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
Integrating Buprenorphine Into the SFGH AIDS Program